Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

Original languageEnglish (US)
Article number39
JournalCurrent Infectious Disease Reports
Issue number8
StatePublished - Aug 23 2015


  • Antibiotics
  • Outcomes
  • Ventilator-associated pneumonia

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?'. Together they form a unique fingerprint.

Cite this